(temsirolimus) to treat renal cell carcinoma, which is a type of aggressive
Torisel has been shown to increase patients' survival time, notes Steven
Galson, MD, MPH, who directs the FDA's Center for Drug Evaluation and
"We have made significant advances in the battle against kidney cancer.
Torisel is the third drug approved for this indication in the past 18
months," says Galson in an FDA news release.
Torisel's maker, Wyeth Pharmaceuticals, says it expects the drug to be
available by July.
Torisel inhibits a protein called mTOR that regulates cell production, cell
growth, and cell survival.
The FDA approved Torisel based on a clinical trial of 626 patients split
into three groups. One group of patients only took Torisel. Another group only
took a comparison drug called interferon alpha. Patients in the third group
took a combination of Torisel and interferon.
Most patients who only took Torisel lived at least 11 months, compared with
7.3 months for those who only took interferon. That's a difference of about 3.5
In addition, renal cell carcinoma generally took about two months longer to
worsen in patients who only received Torisel, compared with those who were only
The Torisel-interferon combination didn't significantly improve
The most common adverse reactions, occurring in at least 30% of
Torisel-treated patients in the clinical trial, were rash, fatigue, mouth
sores, nausea, edema, and loss of appetite.
Renal cell carcinoma, diagnosed in about 51,000 people annually in the U.S.,
accounts for about 85% of all U.S. adult kidney cancer, according to the
By Miranda Hitti
Reviewed by Brunilda Nazario
B)2005-2006 WebMD, Inc. All rights reserved